Today: 21 July 2026
Browse Category

Pharmaceuticals 3 November 2025 - 11 November 2025

enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene Holdings Inc. reported fresh preliminary data this morning from the pivotal cohort of its Phase 2 LEGEND trial of detalimogene voraplasmid in high‑risk, BCG‑unresponsive non‑muscle invasive bladder cancer with CIS. The readout shows a 62% complete response at 6 months, 56% at 3 months and 63% CR at any time under the trial’s amended protocol—plus a favorable safety profile. The company completed enrollment of 125 patients in the pivotal cohort, above target, and will refine its analysis with FDA input on the statistical analysis plan. Business Wire
11 November 2025
···
Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly and Company opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and captured an analyst upgrade with a higher price target—moves that had LLY trading sharply higher intraday. Reuters+2
10 November 2025
······
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Late Friday, Metsera accepted a sweetened offer from Pfizer: $65.60 per share in cash plus a contingent value right of up to $20.65 per share, valuing the biotech at up to $10 billion. On Saturday, Novo Nordisk said it would not increase its bid and exited the race, citing legal and regulatory risks tied to its two‑step proposal. Metsera’s board said Pfizer’s amended agreement carries lower antitrust risk and recommended shareholders approve it at a Nov. 13 meeting. PR Newswire+1
8 November 2025
···
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer Inc. has secured a definitive agreement to acquire weight‑loss biotech Metsera in a transaction valued at up to $10 billion, ending a high‑stakes bidding war with Novo Nordisk and positioning Pfizer squarely back in the fast‑growing obesity market. Metsera accepted Pfizer’s revised offer late Friday; Novo said today it would not raise its competing bid. Reuters
8 November 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 7, 2025): NVO Slips as U.S. Wegovy/Ozempic Price Cuts Take Center Stage; Medicare Coverage, FTC Scrutiny and Metsera Bid in Focus

Summary: Novo Nordisk’s U.S.-listed shares traded lower on Friday after the company and Eli Lilly agreed to cut U.S. prices on GLP‑1 medicines to expand access, including under Medicare. The deal introduces near‑term revenue pressure but could lift volumes over time. Investors are also watching a court decision that favored Novo in its bid for obesity biotech Metsera and closely reading this week’s Q3 update and guidance cut. Investopedia+3Reuters+3Novo Nordisk+3
7 November 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors

TL;DR: Novo Nordisk’s U.S.‑listed shares swung after the White House announced a pricing-and-access deal with Novo and Eli Lilly that expands Medicare coverage for anti‑obesity drugs and cuts out‑of‑pocket costs. As of 17:51 UTC, NVO traded around $47.30, down ~2.4% on the day. The company confirmed a Medicare Part D pilot beginning in 2026, lower U.S. prices in Medicare/Medicaid and cash channels, and a three‑year tariff exemption—and flagged a low single‑digit drag to 2026 global sales growth. GlobeNewswire
6 November 2025
··
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax, Inc. reported Q3 2025 results and raised its full‑year adjusted revenue framework to $1.04–$1.06 billion. Management cited momentum from licensing, supply, and milestone revenue—while excluding Sanofi‑led sales and royalties from the outlook. The company also reaffirmed 2025 operating‑expense guidance. ir.novavax.com
6 November 2025
·····
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna, Inc. posted third‑quarter 2025 revenue of ~$1.02 billion and a GAAP loss of $0.51 per share, topping Wall Street estimates as sales of its updated COVID‑19 vaccine outperformed. The company narrowed its full‑year revenue range to $1.6–$2.0 billion, cut operating‑expense guidance, and raised its year‑end cash outlook. Shares popped in pre‑market trading before wobbling intraday. SEC+1
6 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

1) Court clears the way for Metsera to pivot to Novo’s richer bid.On Wednesday evening, the Delaware Chancery Court denied Pfizer’s TRO request that sought to keep Metsera bound to its earlier merger agreement with Pfizer. In a same‑day statement, Pfizer argued the decision “does not address the merits” and vowed to pursue its claims in parallel antitrust litigation. BioSpace’s Thursday write‑up and the company’s press release confirm the ruling and Pfizer’s plan to keep fighting. BioSpace+1
6 November 2025
····
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence for its COVID-19 vaccine and antiviral pill. However, with the pandemic’s tide receding, Pfizer’s stock has faced significant challenges in 2023–2025. Shares that once traded above $50 during the vaccine rollout now hover in the mid-$20sreuters.com. At around $24–$25 per share, Pfizer’s market cap is about $138 billionstockanalysis.com – substantially smaller than several years ago and dwarfed by newer pharma stars.
5 November 2025
··
Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven’s recent troubles center on VYGLXIA – its lead drug candidate for spinocerebellar ataxia, a degenerative brain disorder that currently has no approved treatmentreuters.com. On November 4, 2025, after market close, Biohaven announced that the FDA had issued a Complete Response Letter rejecting the company’s New Drug Application. This CRL cited multiple concerns with Biohaven’s data: potential bias, design limitations, lack of pre-specification, and unmeasured confounding factors in the supporting studiesstocktwits.comstocktwits.com. In simpler terms, the FDA was uneasy with how Biohaven ran and analyzed its trials – particularly its use of real-world evidence and an external control group instead of a standard placebo-controlled trialreuters.com.
5 November 2025
·
Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva’s financial turnaround appears to be gaining steam, driven by both top-line growth and disciplined cost management. Quarterly revenue has now grown year-over-year for 11 straight quartersinvesting.com, marking a sustained rebound after a difficult past decade. In Q3 2025, revenue rose ~3% YoY to $4.48 Binvesting.com, while adjusted earnings jumped to $0.78 per sharereuters.com. Notably, this beat Wall Street estimates by ~$0.10 and marked Teva’s strongest earnings surprise of 2025reuters.com. The growth engines are Teva’s newer branded drugs: movement-disorder treatment Austedo, migraine injection Ajovy, and schizophrenia depot UZEDY. Together these “innovative medicines” climbed 33% YoY and contributed $830 M this quarterinvesting.com, helping offset flat-to-declining sales in older generic categories. “Our key innovative brands…delivered a 33% increase…underscoring their impact on both patient outcomes and our financial performance,” CEO Richard Francis notedtevapharm.comtevapharm.com. Importantly, Austedo’s momentum led management to raise Austedo’s 2025 revenue outlook to $2.05–$2.15 Binvesting.com. This bodes well for continued earnings expansion, since these specialty products carry higher margins than commodity generics.
5 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market valuereuters.com. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic became global sensations, with millions seeking their dramatic weight-loss benefits. However, 2025 has seen a sharp reversal of fortune. A “slew of headwinds has shaken investor confidence” in Novo Nordisk’s once-dominant growth storystockanalysis.com. The company’s share price has plummeted nearly 50% year-to-date amid signs that demand growth is slowing and profitability is coming under pressurereuters.com.
5 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

The fight for Metsera is driven by fierce competition in GLP-1 obesity drugs. Novo Nordisk is the maker of Wegovy/Ozempic, and Eli Lilly’s drugs recently overtook Wegovy in US market sharereuters.com. Novo’s new CEO Mike Doustdar and the company’s controlling foundation have pushed for bolder moves after days of sliding market performancereuters.comreuters.com. In late October, Novo – which had already agreed a separate $5 billion deal to buy diabetes biotech Akero – suddenly “launched a bid…valuing [Metsera] at some $9 billion and crashing Pfizer’s deal”reuters.com. This was weeks after Novo’s top shareholder overhauled its board to demand a faster turnaround in the weight-loss arenareuters.comreuters.com.
4 November 2025
···
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer delivered a positive surprise in Q3 2025, topping earnings and revenue expectations even as its overall results declined from a year ago. Adjusted earnings per share came in at $0.87, comfortably above consensusreuters.com. This was achieved on quarterly revenue of about $16.7 billion, which, while ~6% lower than the same period last year, slightly exceeded analysts’ forecastsstocktwits.comreuters.com. The decline was largely anticipated due to the sharp drop in COVID-19 product demand, but stronger-than-expected sales in other areas helped Pfizer beat the Street’s estimates.
4 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peaksharewise.com. In the past three years, the shares have tumbled about 50% as the company’s COVID-fueled revenue boom faded and investors braced for patent expirationssharewise.com. By mid-2025, Pfizer traded near multi-year lows, though it bounced off those lows in early October after positive news on earnings and policy. Notably, Pfizer’s stock surged ~15% at the end of Q3 when it announced the drug pricing agreement and broader market sentiment toward pharma improved. However, renewed concerns – including a light prescription uptake for the latest COVID booster and uncertainty around Q3 earnings – saw the stock drift back to the mid-$24 range by early Novemberstatmuse.comstatmuse.com.
3 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics’ stock price has been on a tear in late 2025, turning heads in the biotech investing community. After languishing under $1 for most of the year, RANI exploded upward in October. It closed on Oct 31 at $2.20, up +51.7% in one dayfinviz.com on massive volume. In fact, over the past month RANI has climbed about 335%finviz.com. Just a few weeks ago in early October it was trading around 50–60 cents; by the first week of November it’s oscillating in the mid-$2s. As of Nov 3, the stock is indicated around $2.50futunn.com – a stunning short-term gain, though still a far cry from its IPO price.
3 November 2025
··
1 … 38 39 40 41 42 … 44
Go toTop